NCT06348290 2024-04-04
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
Jemincare
Phase 1 Unknown
Clinical Trials
12 trialsNCT06232863 2024-02-02
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Zhuhai Beihai Biotech Co., Ltd
Phase 1 Unknown
NCT05388487 2024-01-16
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
HighField Biopharmaceuticals Corporation
Phase 1 Unknown
NCT06056323 2023-10-23
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT04053673 2023-03-28
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Ribon Therapeutics, Inc.
Phase 1 Unknown
NCT05759234 2023-03-08
A Study of HS248 in Patients With Advanced Solid Tumors
Hanhui Pharmaceutical Co., Ltd
Phase 1 Unknown
NCT05442996 2022-07-05
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05060263 2021-09-29
A Study of of HOT1030 in Patients With Advanced Solid Tumors
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT04169178 2020-05-01
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
Henlix, Inc
Phase 1 Unknown
NCT03160833 2020-02-13
A Study of HMPL-453 in Patients With Advanced Solid Malignancies
Hutchmed
Phase 1/2 Unknown
NCT03398720 2018-01-12
Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03030001 2017-01-24
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
Ningbo Cancer Hospital
Phase 1/2 Unknown